

What is claimed is

1. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill
5 Fusobacterium varium cells.
2. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can neutralize the toxin produced by Fusobacterium varium cells.
3. A pharmaceutical composition of treatment for a patient with
10 ulcerative colitis comprising a drug which can inhibit the adhesion of Fusobacterium varium cells to the intestinal mucosa.
4. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can inhibit the invasion of Fusobacterium varium cells into the intestinal mucosa.
- 15 5. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 1.
6. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 2.
7. A vaccine for preventing ulcerative colitis from infection with
20 Fusobacterium varium comprising a drug as set forth in claim 3.
8. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 4.
9. A method for screening a drug for selectively killing Fusobacterium varium cells comprising the step of administering a drug to be examined
25 to an experimental model of Fusobacterium varium-infection to thus select a drug, which can selectively kill the bacterium.
10. A method for screening a therapeutic agent for ulcerative colitis comprising the step of administering a candidate drug which selectively

kills the bacterium in a patient with ulcerative colitis and positive to Fusobacterium varium to thus select a drug capable of improving the symptoms of the patients suffering from the disease.

11. An animal as a model of ulcerative colitis obtained by administering
5 a toxin produced by Fusobacterium varium to an animal.

12. The animal model of ulcerative colitis as set forth in claim 11,
wherein the toxin is butyric acid.

13. An animal as a model for ulcerative colitis comprising living
Fusobacterium varium cells adhered to the mucosa.

10 14. A method for making a diagnosis of ulcerative colitis comprising the
step of detecting an antibody against Fusobacterium varium.

15. An agent for making a diagnosis of ulcerative colitis comprising an
antibody against Fusobacterium varium, which has the highest detection
sensitivity and the highest specificity.

15

added
AS

